8-K: Simulations Plus Reschedules Q3 2025 Earnings Release, Reaffirms Revenue Guidance Amid Filer Status Change

Simulations Plus, Inc. has rescheduled its third quarter fiscal 2025 earnings release and conference call to July 14-15, 2025, citing its transition to a non-accelerated filer status, while reaffirming its preliminary Q3 and full-year 2025 revenue guidance.

Summary

• Simulations Plus, Inc. (Nasdaq: SLP) has rescheduled the release of its financial results and conference call for the third fiscal quarter ended May 31, 2025.
• The earnings release, originally scheduled for July 2, 2025, is now expected before market open on Tuesday, July 15, 2025.
• The conference call, also originally set for July 2, 2025, is now scheduled for Monday, July 14, 2025, at 5:00 p.m. Eastern Time.
• The rescheduling is attributed to the Company's transition from a large accelerated filer to a non-accelerated filer, allowing it to utilize the maximum time permitted by regulation for filing.
• The Company reaffirmed its preliminary third quarter fiscal 2025 revenue, expecting it to be in the range of $19 million to $20 million.
• Full year fiscal 2025 revenue guidance was also reaffirmed, with expectations ranging between $76 million and $80 million.
• The preliminary revenue figures are unaudited, based on currently available information, and subject to adjustment in the final financial statements.

Sentiment

Score: 6

Explanation: The delay in the earnings release is a minor negative, but it is clearly explained by a regulatory transition. This negative is largely offset by the positive reaffirmation of both quarterly and full-year revenue guidance, suggesting financial performance remains on track.

Positives

• The Company reaffirmed its preliminary third quarter fiscal 2025 revenue guidance in the range of $19 million to $20 million.
• The Company reaffirmed its full year fiscal 2025 revenue guidance in the range of $76 million to $80 million.
• A clear, regulatory-driven reason (transition to non-accelerated filer status and utilizing allowed time) was provided for the delay, mitigating potential negative speculation.

Negatives

• The release of third quarter fiscal 2025 financial results and the associated conference call have been delayed from July 2, 2025, to July 14-15, 2025.

Risks

• The effectiveness of the Company's new operational structure.
• The Company's ability to maintain its competitive advantages.
• Customer acceptance of new software and improved versions of existing software.
• The general economics of the pharmaceutical industry.
• The Company's ability to finance growth.
• The Company's ability to continue to attract and retain highly qualified technical staff.
• General market conditions and macroeconomic factors.
• The existence of a sustainable market for the Company's products and services.
• Preliminary financial results are unaudited and subject to change, with actual financial results potentially differing materially from estimates.

Future Outlook

The company reaffirmed its preliminary third quarter fiscal 2025 revenue guidance of $19 million to $20 million and its full year fiscal 2025 revenue guidance of $76 million to $80 million. These figures are preliminary, unaudited, and subject to adjustment in the final financial statements.

Industry Context

Simulations Plus operates as a leading provider of cheminformatics, biosimulation, and medical communications solutions to the biopharma industry. Its offerings include advanced software and consulting services that support drug discovery, development, clinical trials, regulatory submissions, and commercialization, leveraging technologies like AI/ML and physiologically based modeling. This announcement, while administrative, indicates the company's continued operations within this specialized and critical sector, with reaffirmed revenue guidance suggesting ongoing performance in line with prior expectations.

Stakeholder Impact

• Shareholders: May experience temporary uncertainty due to the delay, but the reaffirmation of revenue guidance should provide reassurance regarding the company's financial trajectory.
• Investors and Analysts: Will need to adjust their schedules to attend the rescheduled conference call and review the delayed financial results.

Next Steps

• Hold the third quarter fiscal 2025 conference call on Monday, July 14, 2025, at 5:00 p.m. Eastern Time.
• Issue the third quarter fiscal 2025 financial results before market open on Tuesday, July 15, 2025.
• File the Company's Quarterly Report on Form 10-Q for the third quarter fiscal 2025 by July 15, 2025.

Key Dates

Recommendation

Keywords

Simulations Plus, SLP, SEC filing, 8-K, earnings release, financial results, Q3 2025, fiscal 2025, revenue guidance, biosimulation, cheminformatics, biopharma, software, consulting services, drug discovery, drug development, AI/ML, pharmacokinetics, regulatory submissions, non-accelerated filer